首页/数据集/Supplementary Data Ulrich et al 2018 Non-clinical Safety Assessment of CFZ533

Supplementary Data Ulrich et al 2018 Non-clinical Safety Assessment of CFZ533

Dryad2018-01-01 更新2026-04-13 收录

药物安全性评估

临床前研究

数据链接：

https://datadryad.org/resource/doi:10.5061/dryad.f26s174/2 数据链接链接失效反馈

官方服务：

资源简介：

Supplemental Data to Ulrich et al., 2018: Non-clinical Safety Assessment of CFZ533

应用场景：

创建时间：

2018-01-01

特应性皮炎

药物安全性评估

A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). Overall design: Patients were ra

NIAID Data Ecosystem100

Pre-clinical Mouse Studies MSI Compliance

代谢组学标准

临床前研究

Raw data describing pre-clinical Mus musculus studies compliance with the Pre-clinical Metabolomics Standards Initiative (MSI) reporting standards. If metadata is reported in accordance with the MSI g

Figshare2017-09-22 更新70

Experimental design of mouse treatment groups.

MPSIIID酶替代疗法

临床前研究

Mucopolysaccharidosis type IIID (MPS IIID; Sanfilippo D) is caused by biallelic pathogenic variants in N-acetylglucosamine-6-sulfatase (GNS), which participates in catabolism of heparan sulfate (HS) g

Figshare2025-07-25 更新40

Supplementary tables of results from systematic reviews and meta-analyses

查加斯病

临床前研究

Information from the systematic analysis of Chagas Disease treatment possibilities applied to preclinical research with animal models.

DataCite Commons2025-06-01 更新80

Additional file 1 of Can harmonisation of outcomes bridge the translation gap for pre-clinical research? A systematic review of outcomes measured in mouse models of type 2 diabetes

糖尿病动物模型

临床前研究

Additional file 1. Included Studies

NIAID Data Ecosystem50